FPAS
TEVA icon

Focus Partners Advisor Solutions’s Teva Pharmaceuticals TEVA Stock Holding History

Focus Partners Advisor Solutions’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
9,587
+523
+6% +$17.4K ﹤0.01% 974
2026
Q1 		$273K Buy
9,064
+386
+4% +$12.4K ﹤0.01% 1017
2025
Q4 		$271K Buy
+8,678
New +$214K ﹤0.01% 917
2025
Q2 		– Sell
-12,697
Closed -$195K – 1168
2025
Q1 		$195K Buy
12,697
+123
+1% +$2.2K ﹤0.01% 926
2024
Q4 		$277K Buy
+12,574
New +$229K ﹤0.01% 622

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Focus Partners Advisor Solutions's TEVA Position: Q2 2026 in Review

Focus Partners Advisor Solutions increased its Teva Pharmaceuticals (TEVA) stake by 5.8% in Q2 2026, buying an estimated $17.4K and bringing the position to 9,587 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Focus Partners Advisor Solutions first reported a position in TEVA in Q4 2024 and has held it in 5 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Focus Partners Advisor Solutions held 9,587 shares of Teva Pharmaceuticals worth $325K as of Q2 2026.
  • Focus Partners Advisor Solutions bought 523 Teva Pharmaceuticals shares in Q2 2026, an estimated $17.4K.
  • Teva Pharmaceuticals made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #974 holding.
  • Focus Partners Advisor Solutions first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.